Overview

Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

This Study compares two ZD4054 (Zibotentan) doses (10mg and 30mg) with a placebo and a positive control to look at ZD4054 (Zibotentan)'s effect on the ECG of Healthy Volunteer

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination